Eyenovia Stock Today
| EYEN Stock | USD 1.65 0.03 1.85% |
PerformanceVery Weak
| Odds Of DistressHigh
|
Eyenovia is selling at 1.65 as of the 16th of March 2025; that is 1.85 percent increase since the beginning of the trading day. The stock's open price was 1.62. Eyenovia has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York. Eyenovia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 2.09 M outstanding shares of which 249.41 K shares are currently shorted by private and institutional investors with about 0.9 trading days to cover. More on Eyenovia
Moving against Eyenovia Stock
Eyenovia Stock Highlights
| President CEO | Michael Rowe |
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Eyenovia (EYEN) is traded on NASDAQ Exchange in USA. It is located in 295 Madison Avenue, New York, NY, United States, 10017 and employs 57 people. Eyenovia is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.45 M. Eyenovia conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 2.09 M outstanding shares of which 249.41 K shares are currently shorted by private and institutional investors with about 0.9 trading days to cover.
Eyenovia currently holds about 21.51 M in cash with (23.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.63.
Check Eyenovia Probability Of Bankruptcy
Ownership AllocationRoughly 95.83 percent of Eyenovia outstanding shares are held by general public with 0.8 (percent) owned by insiders and only 3.37 % by other corporate entities.
Check Eyenovia Ownership Details
Eyenovia Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Eyenovia market risk premium is the additional return an investor will receive from holding Eyenovia long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.13) | |||
| Jensen Alpha | (1.82) | |||
| Total Risk Alpha | (0.35) | |||
| Treynor Ratio | 1.24 |
Eyenovia Stock Against Markets
Eyenovia Corporate Management
| Andrew Jones | Chief Officer | Profile | |
| Bren Kern | VP Operations | Profile | |
| Enrico Brambilla | Senior RD | Profile | |
| Tony Cardinale | Vice Sales | Profile | |
| Norbert Lowe | Senior Operations | Profile | |
| Alexander Lobo | Investor Contact | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyenovia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyenovia. If investors know Eyenovia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyenovia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eyenovia is measured differently than its book value, which is the value of Eyenovia that is recorded on the company's balance sheet. Investors also form their own opinion of Eyenovia's value that differs from its market value or its book value, called intrinsic value, which is Eyenovia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyenovia's market value can be influenced by many factors that don't directly affect Eyenovia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyenovia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyenovia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyenovia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.